Nabriva Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference
April 19 2017 - 7:00AM
Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage
biopharmaceutical company engaged in the research and development
of novel anti-infective agents to treat serious infections, with a
focus on the pleuromutilin class of antibiotics, today announced
that Colin Broom, M.D., chief executive officer of Nabriva
Therapeutics, will provide a company overview and business update
at the Deutsche Bank 42nd Annual Health Care Conference on
Wednesday, May 3, 2017 at 4:10 p.m. ET. The conference is being
held at the InterContinental Boston hotel in Boston, MA.
The presentation will be webcast live and may be accessed by
visiting the "Investors" section of the Company’s web site under
the "Events and Presentations" tab at http://investors.nabriva.com.
A replay of the webcast will be available for 90 days.
About Nabriva Therapeutics AG
Nabriva Therapeutics is a clinical stage biopharmaceutical
company engaged in the research and development of novel
anti-infectives to treat serious bacterial infections, with a focus
on the pleuromutilin class of antibiotics. Nabriva Therapeutics’
medicinal chemistry expertise has enabled targeted discovery of
novel pleuromutilins, including both intravenous and oral
formulations of its lead product candidate. Nabriva Therapeutics’
lead product candidate, lefamulin, is a novel semi-synthetic
pleuromutilin antibiotic with the potential to be the
first-in-class available for systemic administration in
humans. The Company believes that lefamulin is the first
antibiotic with a novel mechanism of action to have reached
late-stage clinical development in more than a
decade. Lefamulin is currently being evaluated in two global,
registrational Phase 3 clinical trials in patients with moderate to
severe CABP. Nabriva Therapeutics believes lefamulin is well
positioned for use as a first-line empiric monotherapy for the
treatment of moderate to severe CABP due to its novel mechanism of
action, targeted spectrum of activity, resistance profile,
achievement of substantial drug concentration in lung tissue and
fluid, oral and IV formulations and a favorable tolerability
profile. Nabriva Therapeutics intends to further pursue development
of lefamulin for additional indications, including the treatment of
acute bacterial skin and skin structure infections (ABSSSI), and is
developing a formulation of lefamulin appropriate for pediatric
use.
Nabriva Therapeutics owns exclusive, worldwide rights to
lefamulin, which is protected by composition of matter patents
issued in the United
States, Europe and Japan.
Forward Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Nabriva, including but not limited to
statements about the development of Nabriva’s product candidates,
such as plans for the design, conduct and timelines of Phase 3
clinical trials of lefamulin for CABP, the clinical utility of
lefamulin for CABP and Nabriva’s plans for filing of regulatory
approvals and efforts to bring lefamulin to market, the development
of lefamulin for additional indications, the development of
additional formulations of lefamulin, plans to pursue research and
development of other product candidates, the sufficiency of
Nabriva’s existing cash resources and other statements containing
the words “anticipate,” “believe,” “estimate,” “expect,” “intend,”
“may,” “plan,” “predict,” “project,” “target,” “potential,”
“likely,” “will,” “would,” “could,” “should,” “continue,” and
similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including: the uncertainties inherent in the initiation
and conduct of clinical trials, availability and timing of data
from clinical trials, whether results of early clinical trials or
trials in different disease indications will be indicative of the
results of ongoing or future trials, uncertainties associated with
regulatory review of clinical trials and applications for marketing
approvals, the availability or commercial potential of product
candidates including lefamulin for use as a first-line empiric
monotherapy for the treatment of moderate to severe CABP, the
sufficiency of cash resources and need for additional financing and
such other important factors as are set forth under the caption
"Risk Factors" in Nabriva’s annual report on Form 10-K filed with
the U.S. Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent
Nabriva’s views as of the date of this release. Nabriva anticipates
that subsequent events and developments will cause its views to
change. However, while Nabriva may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Nabriva’s views as of any date subsequent to the date
of this release.
CONTACT:
INVESTOR RELATIONS
Will Sargent
Nabriva Therapeutics AG
William.Sargent@nabriva.com
610-813-6406
MEDIA
Katie Engleman
Pure Communications, Inc.
Katie@purecommunicationsinc.com
910-509-3977
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Apr 2023 to Apr 2024